Heart surrounded by blue light

Milrinone: A Powerful Ally in the Fight Against Chronic Heart Failure

Kai Mendoza in Health & Wellness October 2026 • 4 min read.

"Discover how milrinone can improve heart function and reduce inflammation in patients battling chronic heart failure."

Chronic heart failure is a widespread and serious condition where the heart struggles to pump blood effectively, leading to a cascade of health issues. While treatments like diuretics and digitalis have their place, they aren't suitable for everyone and can even trigger new problems. This creates a need for more effective and universally applicable therapies.

Inflammation plays a major role in worsening chronic heart failure. When the body's inflammatory response goes into overdrive, it elevates levels of substances like cystatin C (Cys-C), which in turn fuels further heart damage. This creates a destructive cycle where inflammation worsens heart function, leading to more inflammation and further decline.

But there's good news. A study has explored the potential of milrinone, a drug known for its ability to boost heart function, to break this cycle. The research dives into how milrinone affects key inflammatory markers and overall heart performance, offering hope for improved treatment strategies for chronic heart failure.

AI Search Multiple angles on this topic

Stats & Impact

Reported Hemodynamic Changes

A retrospective cohort of 69 patients with acute heart failure listed for transplant and bridged with continuous milrinone infusion reported approximately 20% reductions in ventricular pressures and pulmonary and systemic vascular resistance. The cohort also showed an almost 20% increase in cardiac index. These figures describe the patients in that cohort, not a universal effect.

Milrinone's Impact: Reducing Inflammation and Boosting Heart Function

The study, conducted at Shouguang People's Hospital in China, involved 70 patients diagnosed with chronic heart failure. These individuals were randomly divided into two groups: a treatment group receiving milrinone in addition to standard heart failure therapy, and a control group receiving standard therapy alone. Researchers then meticulously tracked various factors, including levels of specific inflammatory markers and key indicators of cardiac function.

The results were compelling. Patients treated with milrinone experienced a significant reduction in serum levels of interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and cystatin C (Cys-C). These are all key players in the inflammatory process, suggesting that milrinone helps to dampen the body's harmful inflammatory response.

Reduced Inflammation: Milrinone effectively lowered key inflammatory markers.
Improved Heart Function: Cardiac output, stroke volume, and ejection fraction all saw significant increases.
Decreased Heart Strain: Levels of LVDd, LVSd and brain natriuretic peptide (BNP) were significantly reduced, indicating less strain on the heart.

AI Search Multiple angles on this topic

Latest Research

Review of Current Evidence

A review of milrinone in advanced heart failure describes it as a commonly used inotropic agent for symptomatic relief and improved hemodynamics. The review examines its efficacy, indications, patient outcomes, and gaps in the evidence. It also identifies future research directions for better understanding and optimizing milrinone’s role in chronic advanced heart failure.

Counterpoints

Combination With Beta-Blockers

A review reports a synergistic effect of milrinone and β-blockers in patients with heart failure. It presents intravenous milrinone combined with β-blockers as a treatment option that may help patients successfully wean from milrinone. The review qualifies this possibility as applying in some cases, not as a guaranteed outcome.

Comparison

Milrinone and Dobutamine

A December 2022 report says its results support long-term ambulatory milrinone as a bridge to LVAD or transplant, or as an option to improve quality of life for people with advanced heart failure who have no other advanced treatment options. An August 2023 meta-analysis compared milrinone with dobutamine in acute decompensated heart failure and cardiogenic shock. It notes that the impact of these drugs on mortality remains unknown.

Furthermore, the study revealed that milrinone significantly improved cardiac function. Measures like cardiac output, stroke volume, and left ventricular ejection fraction all saw substantial increases in the treatment group compared to the control group. Additionally, markers of heart strain, such as left ventricular end-diastolic diameter (LVDd), left ventricular end-systolic diameter (LVSd), and brain natriuretic peptide (BNP) levels, were significantly reduced, indicating that milrinone helps ease the burden on the heart.

A Brighter Future for Heart Failure Patients

This study provides compelling evidence that milrinone can be a valuable addition to the treatment arsenal for chronic heart failure. By targeting both inflammation and cardiac function, milrinone offers a dual-action approach that can lead to significant improvements in patient outcomes.

While the study's findings are promising, it's important to remember that this is just one piece of the puzzle. Further research is needed to explore the long-term effects of milrinone and to determine the optimal dosage and treatment strategies for different patient populations. Larger studies are also needed to confirm these findings and to assess the potential benefits of long-term milrinone use.

Nevertheless, this research offers a beacon of hope for individuals living with chronic heart failure. With continued investigation and refinement, milrinone has the potential to become a cornerstone of heart failure therapy, helping patients live longer, healthier, and more fulfilling lives.

Oral milrinone compared with placebo

28% higherIn a severe chronic heart failure trial, all-cause mortality was 28% higher with oral milrinone than with placebo (95% confidence interval, 1% to 61%).^[1]

Different routes and comparisons, different evidence

A pooled comparison of continuous outpatient intravenous milrinone with dobutamine reported lower crude mortality in the milrinone group. The estimate comes from observational studies, so differences between the groups may have influenced the comparison.^[2]

That pooled result does not cancel the placebo-controlled finding for oral milrinone: the route and comparison differ, and the observational analysis is described as hypothesis-generating rather than definitive.^{[1] [2]}

Milrinone can increase contractility through cyclic AMP, but excessive peripheral vasodilation and hypotension are noted as potential limitations, particularly at high doses.^{[1] [3]}

What the evidence still leaves unresolved

How much of the apparent mortality difference in outpatient intravenous comparisons reflects milrinone itself rather than confounding in observational studies?^[2]
How do route and dose shape the balance between increased contractility and risks from vasodilation or hypotension?^{[1] [3]}

Sources

Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. (www.nejm.org)
The Mortality Benefit of Milrinone as a Continuous Outpatient Intravenous Inotrope Therapy in Advanced Heart Failure: A Systemic Review and Meta-Analysis (pmc.ncbi.nlm.nih.gov)
Milrinone or dobutamine in patients with heart failure: evidence from meta‐analysis (onlinelibrary.wiley.com)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

What is milrinone and what is its role in managing heart failure?

Milrinone is a medication investigated for its potential in treating chronic heart failure. It's known for its ability to boost heart function. The study mentioned explores how milrinone affects inflammatory markers and overall heart performance, potentially offering improved treatment strategies. The research at Shouguang People's Hospital in China involved patients with chronic heart failure, where one group received milrinone, and the other received standard therapy. The results showed significant reductions in inflammatory markers such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and cystatin C (Cys-C) in the milrinone group.

What is chronic heart failure and why is it a concern?

Chronic heart failure is a serious condition where the heart struggles to pump blood effectively. This leads to a variety of health issues. In this context, the importance lies in the widespread nature and the serious health implications. The need for more effective and universally applicable therapies is highlighted, given that treatments like diuretics and digitalis are not suitable for everyone and can trigger new problems. The inability of the heart to pump blood effectively can lead to a cascade of health issues and a significant reduction in quality of life.

How does inflammation affect chronic heart failure and why is it important?

Inflammation plays a significant role in worsening chronic heart failure. When the body's inflammatory response is overactive, it elevates substances like cystatin C (Cys-C), leading to further heart damage. This creates a destructive cycle where inflammation worsens heart function, leading to more inflammation and further decline. The study emphasizes that milrinone's ability to reduce inflammation could break this damaging cycle, improving heart function and outcomes for patients.

What specific measurements or factors were analyzed in the study to evaluate milrinone's effectiveness?

The study measured various factors to assess milrinone's impact. Specifically, researchers tracked levels of specific inflammatory markers and key indicators of cardiac function. The key findings were related to inflammation reduction, improved heart function, and decreased heart strain. Milrinone effectively lowered inflammatory markers such as interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and cystatin C (Cys-C). Cardiac output, stroke volume, and ejection fraction all saw significant increases, while markers of heart strain, like left ventricular end-diastolic diameter (LVDd), left ventricular end-systolic diameter (LVSd), and brain natriuretic peptide (BNP) levels, were significantly reduced.

What are the broader implications of using milrinone in the treatment of heart failure?

The implications of milrinone in the context of chronic heart failure treatment are significant. The study suggests that milrinone can be a valuable addition to the treatment strategies. By targeting both inflammation and cardiac function, milrinone offers a dual-action approach that can lead to significant improvements in patient outcomes. The positive effects of milrinone on reducing inflammation and improving cardiac function suggest a potential for better management of the disease and improved quality of life for patients.